Cabozantinib in progressive medullary thyroid cancer. - Wikidata - wikimedia - TriplyDB

Cabozantinib in progressive medullary thyroid cancer.

Cabozantinib in progressive medullary thyroid cancer.

http://www.wikidata.org/entity/Q34185084

about

Cytotoxic and targeted therapy for hereditary cancers Progress in systemic therapy of advanced hepatocellular carcinoma Contemporary Treatment of Metastatic Renal Cell Carcinoma Endocrine neoplasms in familial syndromes of hyperparathyroidism Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications Profile of nintedanib in the treatment of solid tumors: the evidence to date c-Met as a Target for Personalized Therapy Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses The treatment landscape in thyroid cancer: a focus on cabozantinib Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Sorafenib in metastatic thyroid cancer: a systematic review Cabozantinib for progressive metastatic medullary thyroid cancer: a review Medical management of metastatic medullary thyroid cancer Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma Recent Updates on the Management of Medullary Thyroid Carcinoma Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study.Update: the status of clinical trials with kinase inhibitors in thyroid cancer My, How Things Have Changed in Multiple Endocrine Neoplasia Type 2A!Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.The positive clinical therapeutically effects of Escin on advanced thyroid cancer.

P2860

Q26739366-67ABD356-9069-476E-8B4F-EF6C836C2319 Q26740217-E54B7CFE-C6FD-46B5-B578-AF024AE46A76 Q26740594-CF9F26A3-EFF5-44A5-95C8-2230A5BA7B5E Q26747174-DD0BE7F0-0E07-4187-A83A-ABB17340F1E9 Q26748581-91F31025-2407-4FDE-964D-E537B5F965A4 Q26764892-90825BE2-C161-4D09-8DA5-13ECE7D0F6DA Q26764899-1E7B3CAF-9E4F-4418-BF67-8E25BD80DFDB Q26775134-E964651D-1B81-4806-8154-3CADE5C8D387 Q26775483-CA8C0BA1-02BE-4B5E-8255-887C811DA8E3 Q26781273-E46489D7-45DE-47E6-BE95-D15358F8D6F7 Q26781662-5FCBF306-B783-4376-8512-4D88D440A1FD Q26786243-296A6946-5E11-493A-BE16-AED081E0114C Q26796404-416E3142-A9EE-442E-87DF-1D9757262CED Q26821959-7F956E8D-1304-461A-960E-39FB92CA5EB3 Q26828884-8F1A5724-9B2F-44E4-9583-4DA75EE92179 Q26851709-5EA78596-DB12-42A5-AAC8-C15C2467E81E Q27005897-E73D695A-A5D9-4708-8EBB-DA92E2138BB7 Q28066747-89028CF1-8902-452F-8543-C9DCC7438481 Q28066911-76963285-9483-44EA-B14C-1DE605D5483C Q28070762-E518FE61-1EC1-41DB-9E12-12D5A131A0B8 Q28072166-9F3C3C17-726B-4947-AA47-897BC1761232 Q28072655-0CBA69EF-103F-4ED5-9795-7CD3AC871969 Q28074834-55DE04AD-138E-49A8-9D57-E284A889D237 Q28079328-0423EBB4-1765-4F9C-A2EC-5FEFC7F2B785 Q28397935-3D7A3E55-66C3-47E8-A3AD-2340627C4902 Q28830947-F0B24D84-BDC9-4B27-A8D7-D752BC846E97 Q30250303-4FC5131C-F138-49AD-A0D5-D86E36068356 Q30381368-7775D0A3-BABE-46B3-9BC1-5EC2793ECD25 Q30399006-E752C75D-DB65-4E51-9E45-0B91B7F86212 Q33424270-FC5CB1A1-CB12-49CF-A645-D39A46B94F11 Q33434042-3F0299E1-DBF6-4139-9729-21416AB6ED54 Q33441170-DFBBF3E4-B977-492B-B0F6-920DF99A7B75 Q33465649-68CB6E8B-8CAC-44F0-B5C0-D20B7D6452E7 Q33570056-2D3653B6-A207-4E75-9676-6930C99EFF7F Q33570313-215CDCF8-AC21-4390-8E68-6BFCA3B20C73 Q33587905-D578272A-FDBC-467B-8BC1-2CC381FAB71C Q33599860-C876E399-C53C-4BD2-AE1B-B133D58CAB75 Q33633424-F84DDFD7-73F1-4ACC-AD69-CD250461FC88 Q33677392-D5B61369-7869-4515-B7E4-42F6364D0E0B Q33679565-4176424B-189F-46B9-B0EF-AA9B6BE784E5

P2860

Cabozantinib in progressive medullary thyroid cancer.

http://www.wikidata.org/entity/Q34185084

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Cabozantinib in progressive medullary thyroid cancer.

@ast

Cabozantinib in progressive medullary thyroid cancer.

@en

Cabozantinib in progressive medullary thyroid cancer.

@nl

type

label

Cabozantinib in progressive medullary thyroid cancer.

@ast

Cabozantinib in progressive medullary thyroid cancer.

@en

Cabozantinib in progressive medullary thyroid cancer.

@nl

prefLabel

Cabozantinib in progressive medullary thyroid cancer.

@ast

Cabozantinib in progressive medullary thyroid cancer.

@en

Cabozantinib in progressive medullary thyroid cancer.

@nl

P1433

Q34185084-6EBC221D-C6EE-4D6D-A8B1-62F95859A95F

P1476

Q34185084-4E5EE107-7239-435C-952D-9F3A4BFC183E

P2093

Q34185084-014AD72D-3F22-452A-8B9D-5508F4EC2D96

Q34185084-01B34692-D02D-4A7C-8B83-4C07089B9026

Q34185084-1EF8DD16-AD78-4492-8B0F-7CD086C18C19

Q34185084-367F8810-DFC9-48EE-A034-BA5CD270B3C2

Q34185084-482B6045-2BD1-4F9D-A2C1-0939F0FAE631

Q34185084-578DFC79-37EE-4010-8D34-8F1547FDEFD8

Q34185084-75571842-6882-4AE6-951E-A995C12862C5

Q34185084-9FAC6557-061D-4521-A3AB-7CFD4F064537

Q34185084-ABDBFF51-A3DD-4DF9-8A45-4D74A4EA96D9

Q34185084-BEE92C41-C99C-4645-AE85-7A8FA2CD0B0A

P2860

Q34185084-0F10BA8E-DEE5-4424-8A15-337E257EAAF9

Q34185084-11090889-FC3A-4BDE-8952-4F569089E05A

Q34185084-1A11BCC8-AD88-4F91-A303-25DC1553A24C

Q34185084-2AE583C0-7BCE-4454-AA8C-6F62A957D2EC

Q34185084-2BBCDB19-632B-4BD8-97EC-1258D5153D60

Q34185084-3CC0EF53-7967-4B71-BF69-C22AE0FA1F64

Q34185084-49C0F713-C0F7-4FC0-8EC0-32684E5A5676

Q34185084-4C11C9B8-6DEC-469B-AC6C-309A1D503DF8

Q34185084-5447AE45-69FD-4092-A4B6-C39C2983F0D3

Q34185084-5D612EDF-FB72-4826-8779-19D3D4329EDE

P304

Q34185084-4D1DB07A-ACBE-4A33-93B9-DC28A02B46FB

P31

Q34185084-D18F3AFC-E351-43D7-B2C1-E47E58D25054

P356

Q34185084-7634BBEE-42C2-4D9D-84E5-C98AA847DDD1

P407

Q34185084-DAE49368-EF9A-4715-A15A-2AFB1462CF23

P433

Q34185084-E55B433A-8D3E-4B81-82CA-29EA0906550E

P478

Q34185084-03EB960E-6018-4F7B-B926-EBCD61F98866

P50

Q34185084-0B9AC996-9077-4578-B4AD-29A64CA1A7B2

Q34185084-986359DA-FC70-4D57-B5F8-408121421B26

Q34185084-B4F5F8F7-B6E9-4297-B4B8-3F362F4D6F17

Q34185084-D7254E91-55C2-4706-9140-571BB277E8FF

Q34185084-E9A3BA2D-D5D9-487E-A31A-61941505EBF6

Q34185084-F69BEE01-C3B0-45AB-B3A5-EB09D18A34F7

P577

Q34185084-12D89BA2-9BBD-4257-8027-9CCD6BBA55AE

P5875

Q34185084-CA505E38-7C17-42D4-80B7-0025D039E78D

P698

Q34185084-B0DF8F08-FEB5-49FA-9FA5-9C9CABCDE48E

P932

Q34185084-7B5471A7-D9F7-4465-9DF9-FA06DE71F7FD

P356

JCO.2012.48.4659

P1433

Journal of Clinical Oncology

P1476

Cabozantinib in progressive medullary thyroid cancer.

@en

P2093

Barry Nelkin

http://www.w3.org/2001/XMLSchema#string

Colin Hessel

http://www.w3.org/2001/XMLSchema#string

Douglas Ball

http://www.w3.org/2001/XMLSchema#string

Ezra E W Cohen

http://www.w3.org/2001/XMLSchema#string

Haythem Ali

http://www.w3.org/2001/XMLSchema#string

Lori J Wirth

http://www.w3.org/2001/XMLSchema#string

Manisha H Shah

http://www.w3.org/2001/XMLSchema#string

Marcia S Brose

http://www.w3.org/2001/XMLSchema#string

Martin J Schlumberger

http://www.w3.org/2001/XMLSchema#string

Michael C Kreissl

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level.

Treatment of medullary thyroid carcinoma: an update.

Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.

Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005.

New therapeutic approaches to treat medullary thyroid carcinoma.

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

RET and NTRK1 proto-oncogenes in human diseases.

P304

3639-3646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.48.4659

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Barbara Jarząb

Patrick Schöffski

Steven I. Sherman

Rossella Elisei

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256425447

http://www.w3.org/2001/XMLSchema#string

P698

24002501

http://www.w3.org/2001/XMLSchema#string

P932

4164813

http://www.w3.org/2001/XMLSchema#string